The potent chemotherapeutic agents currently used in the treatment of lung cancer cause considerable destruction to normal cells, severe adverse reactions and unpleasant side effects, and a more effective method to directly target tumors with anti-cancer drugs has long been sought after.
With properties not available from either molecular or macroscopic agents, Astra Logics' Targeted Nano-Particle Drug Delivery system has the ability to deliver these agents selectively direct to the cancer cells, resulting in:
• Lower Effective Dosage • Fewer Unpleasant Side Effects • Less likelihood of cancer cells developing resistance to the drug therapy resulting in better long-term treatment options
By using the unique properties of Graphene oxide nano-particles, anti-cancer agents can concentrate in a cancer cell resulting in extremely high efficacy. Moreover, when this enhanced efficacy is accompanied by reduced uptake of anti-cancer agents by healthy cells, toxicity to normal cells is diminished, minimizing ongoing chemotherapy treatment and the often severe side effects it causes.
Astra Logics will use its breakthrough nano-particle technology to develop a family of cell-selective, targeted drug delivery systems for the treatment of metastatic cancers and welcomes collaboration and partnering opportunities from biopharm enterprises seeking to integrate or combine their drug delivery system or platform with our advanced nano-scale technology.
At Astra Logics, our culture is animated by passion, innovation, and the courage to change the lives of the patients who look to us for better treatments in their pursuit of fuller, healthier lives.